Binding of sodium channel inhibitors to hyperpolarized and depolarized conformations of the channel

N. Lenkey, R. Karoly, N. Epresi, E. Vízi, A. Mike

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Sodium channels are inhibited by a chemically diverse group of compounds. In the last decade entirely new structural classes with superior properties have been discovered, and novel therapeutic uses of sodium channel inhibitors (SCIs) have been suggested. Many promising novel drug candidates have been described and characterized. Published structure-activity relationship studies, pharmacophore models, and mutagenesis studies seem to lag behind, dealing with only a limited group of inhibitor compounds. The abundance of novel compounds requires an organized comparison of drug potencies. The affinity of sodium channel inhibitors can vary typically ten- to thousand-fold depending on the voltage protocol; therefore comparison of electrophysiology data is difficult. In this study we describe a method for standardization of these data with the help of a simple model of state-dependence. We derived hyperpolarized (resting) and depolarized (generally termed " inactivated" ) state affinities for the studied drugs, which made the measurements comparable. We show a rank order of SCIs based on resting and inactivated affinity values. In an attempt to define basic chemical requirements for sodium channel inhibitor activity we investigated the dependence of both resting and inactivated state affinities on individual chemical descriptors. Lipophilicity (most often expressed by the logP value) is the single most important determinant of SCI potency. We investigated the independent impact of several other calculated chemical properties by standardizing drug potencies for logP values. By combining these two approaches: standardization of affinity values, and standardization of potencies, we concluded that while resting affinity is mostly determined by lipophilicity, inactivated state affinity is determined by a more complex interaction of chemical properties, including hydrogen bond acceptors, aromatic rings, and molecular weight.

Original languageEnglish
Pages (from-to)191-200
Number of pages10
JournalNeuropharmacology
Volume60
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Sodium Channel Blockers
Pharmaceutical Preparations
Sodium Channels
Electrophysiology
Therapeutic Uses
Structure-Activity Relationship
Mutagenesis
Hydrogen
Molecular Weight

Keywords

  • Chemical descriptors
  • Inactivated state affinity
  • Local anesthetic
  • Resting affinity
  • Sodium channel inhibitor
  • Structure-activity relationship

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Binding of sodium channel inhibitors to hyperpolarized and depolarized conformations of the channel. / Lenkey, N.; Karoly, R.; Epresi, N.; Vízi, E.; Mike, A.

In: Neuropharmacology, Vol. 60, No. 1, 01.2011, p. 191-200.

Research output: Contribution to journalArticle

@article{809c237362a045ed86f0b12b5c5600be,
title = "Binding of sodium channel inhibitors to hyperpolarized and depolarized conformations of the channel",
abstract = "Sodium channels are inhibited by a chemically diverse group of compounds. In the last decade entirely new structural classes with superior properties have been discovered, and novel therapeutic uses of sodium channel inhibitors (SCIs) have been suggested. Many promising novel drug candidates have been described and characterized. Published structure-activity relationship studies, pharmacophore models, and mutagenesis studies seem to lag behind, dealing with only a limited group of inhibitor compounds. The abundance of novel compounds requires an organized comparison of drug potencies. The affinity of sodium channel inhibitors can vary typically ten- to thousand-fold depending on the voltage protocol; therefore comparison of electrophysiology data is difficult. In this study we describe a method for standardization of these data with the help of a simple model of state-dependence. We derived hyperpolarized (resting) and depolarized (generally termed {"} inactivated{"} ) state affinities for the studied drugs, which made the measurements comparable. We show a rank order of SCIs based on resting and inactivated affinity values. In an attempt to define basic chemical requirements for sodium channel inhibitor activity we investigated the dependence of both resting and inactivated state affinities on individual chemical descriptors. Lipophilicity (most often expressed by the logP value) is the single most important determinant of SCI potency. We investigated the independent impact of several other calculated chemical properties by standardizing drug potencies for logP values. By combining these two approaches: standardization of affinity values, and standardization of potencies, we concluded that while resting affinity is mostly determined by lipophilicity, inactivated state affinity is determined by a more complex interaction of chemical properties, including hydrogen bond acceptors, aromatic rings, and molecular weight.",
keywords = "Chemical descriptors, Inactivated state affinity, Local anesthetic, Resting affinity, Sodium channel inhibitor, Structure-activity relationship",
author = "N. Lenkey and R. Karoly and N. Epresi and E. V{\'i}zi and A. Mike",
year = "2011",
month = "1",
doi = "10.1016/j.neuropharm.2010.08.005",
language = "English",
volume = "60",
pages = "191--200",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Binding of sodium channel inhibitors to hyperpolarized and depolarized conformations of the channel

AU - Lenkey, N.

AU - Karoly, R.

AU - Epresi, N.

AU - Vízi, E.

AU - Mike, A.

PY - 2011/1

Y1 - 2011/1

N2 - Sodium channels are inhibited by a chemically diverse group of compounds. In the last decade entirely new structural classes with superior properties have been discovered, and novel therapeutic uses of sodium channel inhibitors (SCIs) have been suggested. Many promising novel drug candidates have been described and characterized. Published structure-activity relationship studies, pharmacophore models, and mutagenesis studies seem to lag behind, dealing with only a limited group of inhibitor compounds. The abundance of novel compounds requires an organized comparison of drug potencies. The affinity of sodium channel inhibitors can vary typically ten- to thousand-fold depending on the voltage protocol; therefore comparison of electrophysiology data is difficult. In this study we describe a method for standardization of these data with the help of a simple model of state-dependence. We derived hyperpolarized (resting) and depolarized (generally termed " inactivated" ) state affinities for the studied drugs, which made the measurements comparable. We show a rank order of SCIs based on resting and inactivated affinity values. In an attempt to define basic chemical requirements for sodium channel inhibitor activity we investigated the dependence of both resting and inactivated state affinities on individual chemical descriptors. Lipophilicity (most often expressed by the logP value) is the single most important determinant of SCI potency. We investigated the independent impact of several other calculated chemical properties by standardizing drug potencies for logP values. By combining these two approaches: standardization of affinity values, and standardization of potencies, we concluded that while resting affinity is mostly determined by lipophilicity, inactivated state affinity is determined by a more complex interaction of chemical properties, including hydrogen bond acceptors, aromatic rings, and molecular weight.

AB - Sodium channels are inhibited by a chemically diverse group of compounds. In the last decade entirely new structural classes with superior properties have been discovered, and novel therapeutic uses of sodium channel inhibitors (SCIs) have been suggested. Many promising novel drug candidates have been described and characterized. Published structure-activity relationship studies, pharmacophore models, and mutagenesis studies seem to lag behind, dealing with only a limited group of inhibitor compounds. The abundance of novel compounds requires an organized comparison of drug potencies. The affinity of sodium channel inhibitors can vary typically ten- to thousand-fold depending on the voltage protocol; therefore comparison of electrophysiology data is difficult. In this study we describe a method for standardization of these data with the help of a simple model of state-dependence. We derived hyperpolarized (resting) and depolarized (generally termed " inactivated" ) state affinities for the studied drugs, which made the measurements comparable. We show a rank order of SCIs based on resting and inactivated affinity values. In an attempt to define basic chemical requirements for sodium channel inhibitor activity we investigated the dependence of both resting and inactivated state affinities on individual chemical descriptors. Lipophilicity (most often expressed by the logP value) is the single most important determinant of SCI potency. We investigated the independent impact of several other calculated chemical properties by standardizing drug potencies for logP values. By combining these two approaches: standardization of affinity values, and standardization of potencies, we concluded that while resting affinity is mostly determined by lipophilicity, inactivated state affinity is determined by a more complex interaction of chemical properties, including hydrogen bond acceptors, aromatic rings, and molecular weight.

KW - Chemical descriptors

KW - Inactivated state affinity

KW - Local anesthetic

KW - Resting affinity

KW - Sodium channel inhibitor

KW - Structure-activity relationship

UR - http://www.scopus.com/inward/record.url?scp=78149500252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149500252&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2010.08.005

DO - 10.1016/j.neuropharm.2010.08.005

M3 - Article

C2 - 20713065

AN - SCOPUS:78149500252

VL - 60

SP - 191

EP - 200

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 1

ER -